Skip to main content

ARTL

Stock
Health Care
Biotechnology

Performance overview

ARTL Price
Price Chart

Forward-looking statistics

Beta
0.79
Risk
66.34%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.

Company info

SectorHealth Care
IndustryBiotechnology
Employees8
Market cap$4.5M

Fundamentals

Enterprise value$6.6M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity14.57

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$17.94
Dividend per share
Revenue per share
Avg trading volume (30 day)$13M
Avg trading volume (10 day)$39M
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-11.42
Price to sales
P/E Ratio-11.42
Enterprise Value to Revenue
Price to book8.43

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Artelo Biosciences Analyst See It As An Emerging Biotech

Analyst Jason Kolbert upgrades Artelo to Buy with a new $20 price target citing multiple promising drug assets.

Benzinga (July 8, 2025)
New Strong Sell Stocks for April 10th

ASTS, ASEKY and ARTL have been added to the Zacks Rank #5 (Strong Sell) List on April 10, 2025.

Zacks Investment Research (April 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free